Further to the cautionary announcement dated 22 May 2019, wherein the Company advised shareholders that it was engaged in exclusive discussions with a potential partner in Europe as part of the strategic review of its European Commercial Pharmaceuticals business, shareholders are now advised that those discussions have been terminated and as a result caution is no longer required to be exercised when dealing in the Company's securities.

Shareholders are advised that Aspen is now in a position to explore options with other potential partners in order to optimise its European Commercial Pharmaceuticals business.

Click here for original article

Attachments

  • Original document
  • Permalink

Disclaimer

Aspen Pharmacare Holdings Ltd. published this content on 05 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2019 07:02:04 UTC